Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Milo Gatti

Showing results (21-30 of 168) with videos related to

Pageof 17
Sort By:
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 15, 2025
Avoiding resistance development to newer drugs: open research linesMatteo Rinaldi, Milo Gatti, Maddalena Giannella
Intensive Care Medicine|October 13, 2025
Personalizing beta-lactams therapy in critical patients undergoing RRT: moving a further step forward?Tommaso Tonetti, Milo Gatti, Federico Pea
The Journal of Antimicrobial Chemotherapy|November 29, 2023
Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to runMilo Gatti, Pierluigi Viale, Federico Pea
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 8, 2021
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysisMilo Gatti, Emanuel Raschi, Fabrizio De Ponti
Chemotherapy|August 5, 2025
Role of a TDM-guided strategy of isavuconazole for optimizing efficacy/safety outcomes in onco-hematological pediatric patients: a systematic reviewMilo Gatti, Pier Giorgio Cojutti, Federico Pea
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 12, 2025
The importance of antibiofilm antibiotics in hardware-associated infectionsStefano Di Bella, Filippo Mearelli, Milo Gatti
Critical Care (London, England)|April 16, 2024
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysisMilo Gatti, Pier Giorgio Cojutti, Federico Pea
BMC Pharmacology & Toxicology|November 14, 2019
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance studyMilo Gatti, Emanuel Raschi, Fabrizio De Ponti
CNS Drugs|April 18, 2021
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 TherapiesMilo Gatti, Fabrizio De Ponti, Federico Pea
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 29, 2023
Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?Stefano Di Bella, Milo Gatti, Luigi Principe
Pageof 17

Showing results (21-30 of 168) with videos related to

Sort By:
Pageof 17
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 15, 2025
Avoiding resistance development to newer drugs: open research linesMatteo Rinaldi, Milo Gatti, Maddalena Giannella
Intensive Care Medicine|October 13, 2025
Personalizing beta-lactams therapy in critical patients undergoing RRT: moving a further step forward?Tommaso Tonetti, Milo Gatti, Federico Pea
The Journal of Antimicrobial Chemotherapy|November 29, 2023
Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to runMilo Gatti, Pierluigi Viale, Federico Pea
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 8, 2021
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysisMilo Gatti, Emanuel Raschi, Fabrizio De Ponti
Chemotherapy|August 5, 2025
Role of a TDM-guided strategy of isavuconazole for optimizing efficacy/safety outcomes in onco-hematological pediatric patients: a systematic reviewMilo Gatti, Pier Giorgio Cojutti, Federico Pea
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 12, 2025
The importance of antibiofilm antibiotics in hardware-associated infectionsStefano Di Bella, Filippo Mearelli, Milo Gatti
Critical Care (London, England)|April 16, 2024
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysisMilo Gatti, Pier Giorgio Cojutti, Federico Pea
BMC Pharmacology & Toxicology|November 14, 2019
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance studyMilo Gatti, Emanuel Raschi, Fabrizio De Ponti
CNS Drugs|April 18, 2021
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 TherapiesMilo Gatti, Fabrizio De Ponti, Federico Pea
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 29, 2023
Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?Stefano Di Bella, Milo Gatti, Luigi Principe
Pageof 17